British Journal of Pharmacology and Chemotherapy
September 1, 1957
William A. Krivoy
23 citations
Lysergic acid diethylamide (LSD) potentiated the response of guinea‐pig ileum to substance P but not to histamine. It also inhibited the disappearance of substance P when incubated with guinea‐pig brain extract but not when incubated with chymotrypsin. Eserine, morphine, mescaline, chlorpromazine, ergometrine, strychnine and 2 bromo‐LSD did not have this effect. Oxytocin was not destroyed by...
Archives of Neurology And Psychiatry
June 1, 1956
Bert E. Schwarz
49 citations
In a recent report concerning the reversibility by chlorpromazine of psychoses induced by means of mescaline andd-lysergic acid diethylamide (LSD-25), careful attention was given to the clinical and electroencephalographic changes.1Although the clinical changes of this reversal effect were immediate and striking, the conventional electroencephalographic changes were minimal, and it was...
Journal of Mental Science
April 1, 1954
R. A. Sandison, A. M. Spencer, J. D. A. Whitelaw
191 citations
D-lysergic acid diethylamide (LSD 25) was first prepared in 1938 by Stoll and Hofmann. It is the synthetic amide of d-lysergic acid with a secondary amine, diethylamine and belongs to the ergonovine group of ergot alkaloids all of which have lysergic acid as a base. After its ingestion in minute doses, it induces psychic states in which the subject becomes aware of repressed memories and other...
American Journal of Psychiatry
February 1, 1952
Paul H. Hoch, James P. Cattell, Harry H. Pennes
116 citations
The effects of mescaline and lysergic acid were studied in schizophrenic patients. It was found that physiological changes were produced in these patients and that their mental symptomatology was markedly aggravated. The observations made with the above-mentioned drugs on normal individuals were compared with those seen in schizophrenic patients. Mescaline and lysergic acid are drugs that...
Archives of Neurology And Psychiatry
May 1, 1951
Gordon R. Forrer
66 citations
STOLL1studied the effects of lysergic acid diethylamide (LSD-25) in both psychotic and normal subjects. Condrau2and others reported their results of administration of lysergic acid diethylamide to various types of subjects and in general confirmed the findings of Stoll. For details of the chemistry of the ergot alkaloids, we refer to a more recent, comprehensive work by Stoll.3It should be...
Psychedelic Medicine
November 2, 2026
John D. Gault, Erin Almklov, Shirley Tang et al.
Background: Evidence supporting psychedelic-assisted psychotherapy (PAP) for treating posttraumatic stress disorder, depression, and other historically difficult to treat mental health disorders is growing rapidly. Interest from the public and within the US government to provide access to these treatments has also grown. Considering the gap between discovery of effective treatments and...
Zenodo (CERN European Organization for Nuclear Research)
October 30, 2026
Pablo Iturralde, Marcel Pierrelouis, Juan Salvador Hurtado-Silva
preprint
A companion paper argued that biological memory is a third kind of record, neither kept intact nor erased but retained and rewritten by its own consultation, and gave this a readout-write channel on the record in which a consultation opens the record when prediction error crosses a threshold. That channel has no time in it: the gate opens or does not at the instant of reading. Real records do...
Journal of Psychedelic Studies
October 30, 2026
Megan M. Druckrey
Abstract: The aim of this position paper is to explore and discuss the intersection of music therapy and psychedelic-assisted therapy, focusing on the safe and effective use of music during psilocybin treatment. Key points include a historical overview of psychedelic therapy, an examination of current research on the use of music in psychedelic therapy, and a rationale for why an...
Human Figurations
October 30, 2026
Michael Dunning, Jason Hughes, Hannah Farrimond et al.
In April 2026, US President Donald Trump signed an executive order fast-tracking access to psilocybin and ibogaine for the treatment of serious mental illness. This follows decades in which psychedelics had been vilified as a group of drugs entirely lacking in therapeutic potential, associated with counter-cultural groups such as hippies, and whose use was both criminalised and widely...
Brain Sciences
October 29, 2026
Adela G. Buciuc, Mark S. Gold, Brian S Fuehrlein
Substance use disorders remain a leading cause of preventable death, and existing care is better described as disease management than as cure. Medications for opioid, alcohol, and tobacco use disorders reduce substance use, and opioid agonist treatment reduces mortality, yet retention is poor and functional recovery is rarely measured. This review asks whether psychedelics treat addiction, or...